Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 175

1.

Efficacy and Safety of Adding Sitagliptin in Type 2 Diabetes Patients on Insulin: Age-Stratified Comparison at One Year in the ASSIST-K Study.

Takai M, Ishikawa M, Maeda H, Kanamori A, Kubota A, Amemiya H, Iizuka T, Iemitsu K, Iwasaki T, Uehara G, Umezawa S, Obana M, Kaneshige H, Kaneshiro M, Kawata T, Sasai N, Saito T, Takuma T, Takeda H, Tanaka K, Nakajima S, Hoshino K, Honda S, Machimura H, Matoba K, Minagawa F, Minami N, Miyairi Y, Mokubo A, Motomiya T, Waseda M, Miyakawa M, Terauchi Y, Tanaka Y, Matsuba I.

J Clin Med Res. 2019 May;11(5):311-320. doi: 10.14740/jocmr3677. Epub 2019 Apr 14.

2.

Differing Effect of the Sodium-Glucose Cotransporter 2 Inhibitor Ipragliflozin on the Decrease of Fat Mass vs. Lean Mass in Patients With or Without Metformin Therapy.

Nagai Y, Fukuda H, Kawanabe S, Nakagawa T, Ohta A, Tanaka Y.

J Clin Med Res. 2019 Apr;11(4):297-300. doi: 10.14740/jocmr3785. Epub 2019 Mar 18.

3.

Liraglutide Reduces Visceral and Intrahepatic Fat Without Significant Loss of Muscle Mass in Obese Patients With Type 2 Diabetes: A Prospective Case Series.

Ishii S, Nagai Y, Sada Y, Fukuda H, Nakamura Y, Matsuba R, Nakagawa T, Kato H, Tanaka Y.

J Clin Med Res. 2019 Mar;11(3):219-224. doi: 10.14740/jocmr3647. Epub 2019 Feb 13.

4.

Association of the muscle/fat mass ratio with insulin resistance in gestational diabetes mellitus.

Kawanabe S, Nagai Y, Nakamura Y, Nishine A, Nakagawa T, Tanaka Y.

Endocr J. 2019 Jan 28;66(1):75-80. doi: 10.1507/endocrj.EJ18-0252. Epub 2018 Nov 3.

5.

Proposed cut-off value of CA19-9 for detecting pancreatic cancer in patients with diabetes: a case-control study.

Murakami M, Nagai Y, Tenjin A, Tanaka Y.

Endocr J. 2018 Jun 27;65(6):639-643. doi: 10.1507/endocrj.EJ17-0380. Epub 2018 Apr 11.

6.

The impact of aerobic exercise training with vascular occlusion in patients with chronic heart failure.

Tanaka Y, Takarada Y.

ESC Heart Fail. 2018 Aug;5(4):586-591. doi: 10.1002/ehf2.12285. Epub 2018 Mar 25.

7.

Prevalence of Cardiovascular Disease and Its Risk Factors in Primary Aldosteronism: A Multicenter Study in Japan.

Ohno Y, Sone M, Inagaki N, Yamasaki T, Ogawa O, Takeda Y, Kurihara I, Itoh H, Umakoshi H, Tsuiki M, Ichijo T, Katabami T, Tanaka Y, Wada N, Shibayama Y, Yoshimoto T, Ogawa Y, Kawashima J, Takahashi K, Fujita M, Watanabe M, Matsuda Y, Kobayashi H, Shibata H, Kamemura K, Otsuki M, Fujii Y, Yamamoto K, Ogo A, Okamura S, Miyauchi S, Fukuoka T, Izawa S, Yoneda T, Hashimoto S, Yanase T, Suzuki T, Kawamura T, Tabara Y, Matsuda F, Naruse M; Nagahama Study; JPAS Study Group.

Hypertension. 2018 Mar;71(3):530-537. doi: 10.1161/HYPERTENSIONAHA.117.10263. Epub 2018 Jan 22.

PMID:
29358460
8.

Tofogliflozin decreases body fat mass and improves peripheral insulin resistance.

Matsuba R, Matsuba I, Shimokawa M, Nagai Y, Tanaka Y.

Diabetes Obes Metab. 2018 May;20(5):1311-1315. doi: 10.1111/dom.13211. Epub 2018 Feb 4.

9.

Patient rescue and blood utilization in the Ogasawara blood rotation system.

Igarashi T, Fujita H, Asaka H, Takada Y, Ametani R, Naya I, Tanaka Y, Kamesaki M, Kasai A.

Transfusion. 2018 Mar;58(3):788-794. doi: 10.1111/trf.14444. Epub 2018 Jan 7.

PMID:
29315622
10.

Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial.

Ueki K, Sasako T, Okazaki Y, Kato M, Okahata S, Katsuyama H, Haraguchi M, Morita A, Ohashi K, Hara K, Morise A, Izumi K, Ishizuka N, Ohashi Y, Noda M, Kadowaki T; J-DOIT3 Study Group.

Lancet Diabetes Endocrinol. 2017 Dec;5(12):951-964. doi: 10.1016/S2213-8587(17)30327-3. Epub 2017 Oct 24.

PMID:
29079252
11.

Efficacy and safety of switching from basal insulin to once-daily insulin degludec/insulin aspart in Japanese patients with inadequately controlled type 2 diabetes: A 4-week, randomized, open-label, treat-to-target study.

Nagai Y, Nishine A, Hashimoto E, Nakayama T, Sasaki Y, Murakami M, Ishii S, Kato H, Tanaka Y.

J Diabetes Investig. 2017 Sep 16. doi: 10.1111/jdi.12748. [Epub ahead of print]

12.

Effectiveness of Ipragliflozin for Reducing Hemoglobin A1c in Patients With a Shorter Type 2 Diabetes Duration: Interim Report of the ASSIGN-K Study.

Iemitsu K, Kawata T, Iizuka T, Takihata M, Takai M, Nakajima S, Minami N, Umezawa S, Kanamori A, Takeda H, Ito S, Kikuchi T, Amemiya H, Kaneshiro M, Mokubo A, Takuma T, Machimura H, Tanaka K, Asakura T, Kubota A, Aoyanagi S, Hoshino K, Ishikawa M, Matsuzawa Y, Obana M, Sasai N, Kaneshige H, Minagawa F, Saito T, Shinoda K, Miyakawa M, Tanaka Y, Terauchi Y, Matsuba I.

J Clin Med Res. 2017 Sep;9(9):793-801. doi: 10.14740/jocmr3116w. Epub 2017 Jul 27.

13.

Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes.

Ohta A, Kato H, Ishii S, Sasaki Y, Nakamura Y, Nakagawa T, Nagai Y, Tanaka Y.

Expert Opin Pharmacother. 2017 Oct;18(14):1433-1438. doi: 10.1080/14656566.2017.1363888. Epub 2017 Aug 11.

PMID:
28770629
15.

Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus.

Kawata T, Iizuka T, Iemitsu K, Takihata M, Takai M, Nakajima S, Minami N, Umezawa S, Kanamori A, Takeda H, Ito S, Kikuchi T, Amemiya H, Kaneshiro M, Mokubo A, Takuma T, Machimura H, Tanaka K, Asakura T, Kubota A, Aoyanagi S, Hoshino K, Ishikawa M, Matsuzawa Y, Obana M, Sasai N, Kaneshige H, Minagawa F, Saito T, Shinoda K, Miyakawa M, Tanaka Y, Terauchi Y, Matsuba I.

J Clin Med Res. 2017 Jul;9(7):586-595. doi: 10.14740/jocmr3038w. Epub 2017 May 22.

16.

Effect of Ezetimibe Monotherapy on Low-Density Lipoprotein Cholesterol and on Markers of Cholesterol Synthesis and Absorption in Japanese Patients With Hypercholesterolemia.

Ohta A, Kato H, Ishii S, Nagai Y, Tanaka Y.

J Clin Med Res. 2017 Jun;9(6):476-481. doi: 10.14740/jocmr2782w. Epub 2017 Apr 26.

17.

Eating glutinous brown rice for one day improves glycemic control in Japanese patients with type 2 diabetes assessed by continuous glucose monitoring.

Terashima Y, Nagai Y, Kato H, Ohta A, Tanaka Y.

Asia Pac J Clin Nutr. 2017 May;26(3):421-426. doi: 10.6133/apjcn.042016.07.

18.

Controlling Tumor Progression with Cyclophosphamide, Vincristine, and Dacarbazine Treatment Improves Survival in Patients with Metastatic and Unresectable Malignant Pheochromocytomas/Paragangliomas.

Asai S, Katabami T, Tsuiki M, Tanaka Y, Naruse M.

Horm Cancer. 2017 Apr;8(2):108-118. doi: 10.1007/s12672-017-0284-7. Epub 2017 Jan 20.

PMID:
28108930
19.

Effect of 24-week treatment with ipragliflozin on proinsulin/C-peptide ratio in Japanese patients with type 2 diabetes.

Nagai Y, Ohta A, Sada Y, Kato H, Tanaka Y.

Expert Opin Pharmacother. 2017 Jan;18(1):13-17. doi: 10.1080/14656566.2016.1261110. Epub 2016 Nov 21.

PMID:
27841020
20.

Contralateral adrenal suppression on adrenocortical scintigraphy provides good evidence showing subclinical cortisol overproduction from unilateral adenomas.

Katabami T, Ishii S, Obi R, Asai S, Tanaka Y.

Endocr J. 2016 Dec 30;63(12):1123-1132. doi: 10.1507/endocrj.EJ16-0281. Epub 2016 Sep 10.

Supplemental Content

Loading ...
Support Center